Vaxcyte, Inc. (NASDAQ:PCVX) Stock Position Decreased by Headlands Technologies LLC

Key Points

• Headlands Technologies LLC reduced its holdings in Vaxcyte, Inc. by 39.0%, owning 24,052 shares worth $908,000 after selling 15,365 shares during the first quarter.
• Vaxcyte's shares have seen a significant decrease of 9.1% recently, trading at $30.01, while showing a twelve-month range between $27.66 and $121.06.
• Despite the recent decline, Wall Street analysts maintain a positive outlook, with an average buy rating and a price target of $136.50 for Vaxcyte stock.

Headlands Technologies LLC trimmed its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 39.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 24,052 shares of the company's stock after selling 15,365 shares during the period. Headlands Technologies LLC's holdings in Vaxcyte were worth $908,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its stake in shares of Vaxcyte by 0.7% during the first quarter. Vanguard Group Inc. now owns 12,043,805 shares of the company's stock worth $454,774,000 after purchasing an additional 82,118 shares in the last quarter. J. Safra Sarasin Holding AG purchased a new position in Vaxcyte in the 1st quarter worth approximately $470,000. PNC Financial Services Group Inc. boosted its holdings in Vaxcyte by 5.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,600 shares of the company's stock worth $362,000 after acquiring an additional 524 shares during the period. US Bancorp DE grew its position in Vaxcyte by 7.2% in the first quarter. US Bancorp DE now owns 5,344 shares of the company's stock valued at $202,000 after acquiring an additional 357 shares in the last quarter. Finally, XTX Topco Ltd raised its stake in shares of Vaxcyte by 355.9% during the first quarter. XTX Topco Ltd now owns 13,796 shares of the company's stock valued at $521,000 after purchasing an additional 10,770 shares during the period. 96.78% of the stock is owned by hedge funds and other institutional investors.

Vaxcyte Stock Up 1.7%

Shares of PCVX traded up $0.50 during midday trading on Tuesday, hitting $30.17. The company had a trading volume of 758,438 shares, compared to its average volume of 1,780,925. The company's 50 day moving average price is $34.32 and its 200 day moving average price is $47.71. The stock has a market cap of $3.92 billion, a price-to-earnings ratio of -7.32 and a beta of 1.21. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period in the previous year, the company posted ($1.10) earnings per share. Equities analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Cantor Fitzgerald began coverage on shares of Vaxcyte in a report on Tuesday, April 22nd. They set an "overweight" rating for the company. Cowen restated a "buy" rating on shares of Vaxcyte in a research note on Thursday. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $136.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.